27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Vir Biotechnology (NASDAQ:VIR) shares are trading higher on Monday, after the company announced plans to work on coronavirus solutions with GlaxoSmithKline and a $250 million investment from the company.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Vir Biotechnology is a clinical-stage immunology company, developing therapeutic products to treat and prevent serious infectious diseases. The company has grant agreements with Bill & Melinda Gates Foundation.
Vir Biotechnology shares traded up 16.48% to $33.78 at time of publication on Monday. The stock has a 52-week high of $75 and a 52-week low of $11.65.